Results 41 to 50 of about 116 (116)
Accurately assessing glomerular filtration rate (GFR) from plasma creatinine concentrations is challenging in patients with unstable renal function. This study aimed to refine the understanding of creatinine kinetics for more reliable assessments of GFR and net creatinine tubular secretion (nCTS) via OCT2/MATE in humans.
Zhendong Chen+5 more
wiley +1 more source
Abstract Aims Cardiac decompensation in cardiorenal syndrome (CRS) results in systemic congestion usually treated with diuretics. When despite high doses of diuretics, response is poor, ultrafiltration (UF) appears to be a useful and safe technique.
Borja Guerrero Cervera+12 more
wiley +1 more source
The METAB‐HTX trial is a prospective cohort study, evaluating cardiac and systemic metabolism among heart transplant recipients. Myocardial function, energetic and metabolism, allograft vasculopathy, allograft rejection, glucometabolism, lipometabolism, liver‐ and kidney function, leucocyte signatures and thromboinflammation will be evaluated ...
Amin Polzin+21 more
wiley +1 more source
Insulin‐like growth factor‐binding protein‐7 (IGFBP7) and heart failure (HF) risk: the PREVEND study. CI, confidence interval; HR, hazard ratio. Abstract Aim Senescence is a major risk factor for heart failure (HF), and insulin‐like growth factor‐binding protein‐7 (IGFBP7) has been identified as an important senescence‐inducing factor.
Sabrina Abou Kamar+9 more
wiley +1 more source
Markers of progression to heart failure (HF). Gal‐4, galectin‐4; GDF‐15, growth differentiation factor 15; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; ST2, suppression of tumorigenicity‐2. ABSTRACT Aims Biomarkers associated with asymptomatic ventricular dysfunction might improve risk stratification and identify pathways leading to heart ...
Anna Dieden+23 more
wiley +1 more source
Current and novel biomarkers in cardiogenic shock
A summary of current and novel biomarkers and their potential stages of release in cardiogenic shock. The diagram illustrates the proposed release of the biomarkers during the different stages of cardiogenic shock: progression from cardiac dysfunction/stress, through to inflammation and end‐organ dysfunction.
Victor Galusko+5 more
wiley +1 more source
End‐organ protective effect of serelaxin in patients with acute heart failure. CV, cardiovascular; HF, heart failure; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide. Abstract Aims Serelaxin is recombinant human relaxin‐2, a hormone responsible for haemodynamic adaptations and organ protection in pregnancy.
Adriaan A. Voors+12 more
wiley +1 more source
The analysis workflow, findings and potential clinical consequences of iron deficiency in heart failure (HF). From 881 patients with worsening HF, whole blood transcriptome was analysed using the Affymetrix Human Transcriptome Array (HTA) 2.0. Subjects were stratified according to their transferrin saturation (TSAT) levels as iron‐deficient (TSAT <20%)
Niels Grote Beverborg+17 more
wiley +1 more source
Kidney status and events preceding death in heart failure: A real‐world nationwide study
Abstract Aims Chronic kidney disease is a frequent comorbidity in heart failure (HF) patients, affecting prognosis and mortality. This study investigates the relationship between kidney function and adverse kidney events preceding death in HF patients. Methods and results We analysed registry data of HF patients who died between 2014 and 2021, with at ...
Deewa Zahir Anjum+9 more
wiley +1 more source
Heart failure (HF) with supranormal ejection fraction (HFsnEF) is an unnoticed but emerging entity in HF. This study showed that HFsnEF carries a similarly increased cardiovascular risk as HF with reduced ejection fraction (HFrEF) and distinct structural and proteomic characteristics from HFrEF, warranting a further comprehensive understanding and ...
Yasuhiko Sakata+19 more
wiley +1 more source